Cargando…
Ion channels as molecular targets of glioblastoma electrotherapy
Therapies with weak, non-ionizing electromagnetic fields comprise FDA-approved treatments such as Tumor Treating Fields (TTFields) that are used for adjuvant therapy of glioblastoma. In vitro data and animal models suggest a variety of biological TTFields effects. In particular, effects ranging from...
Autores principales: | Abed, Tayeb, Ganser, Katrin, Eckert, Franziska, Stransky, Nicolai, Huber, Stephan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064067/ https://www.ncbi.nlm.nih.gov/pubmed/37006466 http://dx.doi.org/10.3389/fncel.2023.1133984 |
Ejemplares similares
-
Against Repurposing Methadone for Glioblastoma Therapy
por: Vatter, Tatjana, et al.
Publicado: (2020) -
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study
por: Zirjacks, Lisa, et al.
Publicado: (2021) -
Electrotherapies for Glioblastoma
por: Jenkins, Elise P. W., et al.
Publicado: (2021) -
Tumoricidal, Temozolomide- and Radiation-Sensitizing Effects of K(Ca)3.1 K(+) Channel Targeting In Vitro Are Dependent on Glioma Cell Line and Stem Cell Fraction
por: Stransky, Nicolai, et al.
Publicado: (2022) -
Efficacy of combined tumor irradiation and K(Ca)3.1-targeting with TRAM-34 in a syngeneic glioma mouse model
por: Stransky, Nicolai, et al.
Publicado: (2023)